Optimization of the small-scale synthesis of DOTA-Tyr3 -octreotide

The clinical potential of 111In and 90Y labelled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid conjugated Tyr3-octreotide (DOTA-TOC) have been reported in a number of publications, and Phase II clinical trials of 90Y-DOTA-TOC are currently in progress. However, to date, only a summary of...

Full description

Saved in:
Bibliographic Details
Published inNuclear medicine communications Vol. 23; no. 5; p. 493
Main Authors Edreira, M, Melendez-Alafort, L, Mather, S J
Format Journal Article
LanguageEnglish
Published England 01.05.2002
Subjects
Online AccessGet more information

Cover

Loading…
Abstract The clinical potential of 111In and 90Y labelled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid conjugated Tyr3-octreotide (DOTA-TOC) have been reported in a number of publications, and Phase II clinical trials of 90Y-DOTA-TOC are currently in progress. However, to date, only a summary of the large-scale preparation of these radiopharmaceuticals has been published. This publication aims to describe our experience of the small-scale synthesis of DOTA-TOC in the hope that this will assist others in the preparation of this and other similar radioconjugates. DOTA in the form of the tri-t-butyl ester was coupled to the Lys5 (BOC) protected Tyr3-octreotide in N,N-dimethylformamide or N-methyl-2-pyrolidinone, in a three-step reaction involving conjugation, using O-(7-azabenzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU) and diisopropylethyamine (DIPEA) as coupling reagents, deprotection with trifluoroacetic acid and HPLC purification of the conjugates. The product was obtained in final yields of 60+/-5%. The purified product was characterized by mass spectroscopy, showing a molecular weight of 1421.55+/-0.08. In somatostatin receptor binding assays, the unlabelled DOTA-TOC showed an effective displacement of 99mTc labelled HYNIC-TOC (where HYNIC is hydrazinonicotinamide) (IC50=0.31+/-0.07 nm), confirming the retention of receptor-binding affinity. The conjugate could be efficiently labelled with 111In by addition of 111InCl3 and ammonium acetate buffer pH5 and heating (95 degrees C, 20 min).
AbstractList The clinical potential of 111In and 90Y labelled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid conjugated Tyr3-octreotide (DOTA-TOC) have been reported in a number of publications, and Phase II clinical trials of 90Y-DOTA-TOC are currently in progress. However, to date, only a summary of the large-scale preparation of these radiopharmaceuticals has been published. This publication aims to describe our experience of the small-scale synthesis of DOTA-TOC in the hope that this will assist others in the preparation of this and other similar radioconjugates. DOTA in the form of the tri-t-butyl ester was coupled to the Lys5 (BOC) protected Tyr3-octreotide in N,N-dimethylformamide or N-methyl-2-pyrolidinone, in a three-step reaction involving conjugation, using O-(7-azabenzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU) and diisopropylethyamine (DIPEA) as coupling reagents, deprotection with trifluoroacetic acid and HPLC purification of the conjugates. The product was obtained in final yields of 60+/-5%. The purified product was characterized by mass spectroscopy, showing a molecular weight of 1421.55+/-0.08. In somatostatin receptor binding assays, the unlabelled DOTA-TOC showed an effective displacement of 99mTc labelled HYNIC-TOC (where HYNIC is hydrazinonicotinamide) (IC50=0.31+/-0.07 nm), confirming the retention of receptor-binding affinity. The conjugate could be efficiently labelled with 111In by addition of 111InCl3 and ammonium acetate buffer pH5 and heating (95 degrees C, 20 min).
Author Edreira, M
Mather, S J
Melendez-Alafort, L
Author_xml – sequence: 1
  givenname: M
  surname: Edreira
  fullname: Edreira, M
  organization: ICRF Nuclear Medicine Research Laboratory, St Bartholomew's Hospital, London, UK
– sequence: 2
  givenname: L
  surname: Melendez-Alafort
  fullname: Melendez-Alafort, L
– sequence: 3
  givenname: S J
  surname: Mather
  fullname: Mather, S J
BackLink https://www.ncbi.nlm.nih.gov/pubmed/11973491$$D View this record in MEDLINE/PubMed
BookMark eNo1T11LxDAQDHLifehfkP6B6G42TZrH8_RUOOhLfT7aNMVIv2jqQ_31RtSBZWdnhoXZslU_9I6xBOEOweh7iFCCkAsAAWm8eByEC7ZBqYmnSmQrtgGUxEmRWrNtCB8xkpHSV2yNaDRJgxv2kI-z7_xXOfuhT4Ymmd9dErqybXmwZRv50kcp-PBjPubFnhfLRAkf7Dy5Yfa1u2aXTdkGd_O3d-zt-FQcXvgpf3497E_cCiLgKVhLRgFRpoyUlRRGVGBQZkaJsiZE0ZjGOt1AWkmKhnK1k7V2KGsjpNix29-_42fVufo8Tr4rp-X8X0Z8A6OSTMs
CitedBy_id crossref_primary_10_1007_s00259_010_1445_x
crossref_primary_10_1002_chem_200305389
crossref_primary_10_1081_RRS_200040939
crossref_primary_10_1016_S0040_4039_03_00221_1
crossref_primary_10_1038_nprot_2006_175
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.1097/00006231-200205000-00010
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
EISSN 1473-5628
ExternalDocumentID 11973491
Genre Journal Article
GroupedDBID ---
.-D
.Z2
0R~
123
4Q1
4Q2
4Q3
53G
5VS
71W
8L-
8WZ
A6W
AAAAV
AAHPQ
AAIQE
AARTV
AASCR
AAYEP
ABASU
ABBUW
ABDIG
ABJNI
ABVCZ
ABXVJ
ABZAD
ACDDN
ACEWG
ACGFO
ACGFS
ACILI
ACWDW
ACWRI
ACXJB
ACXNZ
ADFPA
ADGGA
ADHPY
ADNKB
AE3
AE6
AEETU
AENEX
AFDTB
AFUWQ
AGINI
AHQNM
AHRYX
AHVBC
AINUH
AJIOK
AJNWD
AJNYG
ALMA_UNASSIGNED_HOLDINGS
ALMTX
AMJPA
AMKUR
AMNEI
AOHHW
AWKKM
BQLVK
BS7
C45
CAG
CGR
COF
CS3
CUY
CVF
DIWNM
DU5
DUNZO
E.X
EBS
ECM
EEVPB
EIF
EJD
EX3
F2K
F2L
F5P
FCALG
FL-
GNXGY
GQDEL
H0~
HLJTE
HZ~
IKREB
IN~
IPNFZ
JF9
JG8
JK3
JK8
K8S
KD2
KMI
L-C
N9A
NPM
N~M
O9-
OAG
OAH
OCUKA
ODA
OL1
OLG
OLV
OLW
OLZ
OPUJH
ORVUJ
OUVQU
OVD
OVDNE
OWU
OWV
OWW
OWX
OWY
OWZ
OXXIT
P-K
P2P
R58
RIG
RLZ
S4R
S4S
T8P
TEORI
TSPGW
V2I
VVN
W3M
WOQ
WOW
X3V
X3W
XXN
XYM
ZA5
ZFV
ZGI
ZZMQN
ID FETCH-LOGICAL-c2330-50cc39603386944b4292b09148962ad3112f9fce7f05b439146ede4d7e14d9242
ISSN 0143-3636
IngestDate Thu May 23 23:52:18 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 5
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c2330-50cc39603386944b4292b09148962ad3112f9fce7f05b439146ede4d7e14d9242
PMID 11973491
ParticipantIDs pubmed_primary_11973491
PublicationCentury 2000
PublicationDate 2002-May
PublicationDateYYYYMMDD 2002-05-01
PublicationDate_xml – month: 05
  year: 2002
  text: 2002-May
PublicationDecade 2000
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Nuclear medicine communications
PublicationTitleAlternate Nucl Med Commun
PublicationYear 2002
SSID ssj0008367
Score 1.6292528
Snippet The clinical potential of 111In and 90Y labelled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid conjugated Tyr3-octreotide (DOTA-TOC) have been...
SourceID pubmed
SourceType Index Database
StartPage 493
SubjectTerms Animals
Heterocyclic Compounds, 1-Ring - chemistry
Indium Radioisotopes - chemistry
Models, Chemical
Models, Molecular
Molecular Weight
Octreotide - analogs & derivatives
Octreotide - chemical synthesis
Octreotide - chemistry
Octreotide - metabolism
Rats
Receptors, Somatostatin - metabolism
Title Optimization of the small-scale synthesis of DOTA-Tyr3 -octreotide
URI https://www.ncbi.nlm.nih.gov/pubmed/11973491
Volume 23
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8QwEA4-QLyI77f04E0ibZI26XF9IcLuXnbBmyRNAsI-ZN2L_nonTfrwiXopJaGl6TeZTCbzzSB0SjMpEiksBts-xoxbgVXCODY5MdwkBeHccYe7vex2yO7u0_smdKhkl8zVefH6Ja_kP6hCG-DqWLJ_QLZ-KTTAPeALV0AYrr_CuA_zfRyIlNVh__NYjkb4GX69cekIoCmkHLnqDzp48DKjZ3hazGdmOn_U7-KAei61sZzVx-0u3LwhjzS2t56Zx7I6UeNJ7brFS5tX3BlJG2rT117lbmlklm7WcAhVeRlIE9NXOx4pphkNaau9smScYrCfRFubevZwkJq0pRqZr4T4SWX7VMDlugm2psOXxGngu_uI1xaST-MSSnf2SZkv8_Vz74dk2lXXIlrkwinEnnPuhIVb0Myz68NQQ-BXlePzq89zOWfDKz_sS0r7ZLCO1sLGIup4KdlAC2ayiVa6AcstdNEWlmhqIwAlaglLVAuL66yFJWoJyzYa3lwPLm9xKKCBC0JpjNO4KChsUSkVWc6YcqXJFBiITOQZkZqCrW1zWxhu41Q5CjbLjDZMwyRlGiYv2UFLk-nE7KGIxZaoRBOttGRFLmQumDHweMK5UVTuo10_-ocnnyXlofovB9_2HKLVRtSO0LKFaWmOwcabq5MSmTeT-0da
link.rule.ids 786
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Optimization+of+the+small-scale+synthesis+of+DOTA-Tyr3+-octreotide&rft.jtitle=Nuclear+medicine+communications&rft.au=Edreira%2C+M&rft.au=Melendez-Alafort%2C+L&rft.au=Mather%2C+S+J&rft.date=2002-05-01&rft.issn=0143-3636&rft.eissn=1473-5628&rft.volume=23&rft.issue=5&rft.spage=493&rft_id=info:doi/10.1097%2F00006231-200205000-00010&rft_id=info%3Apmid%2F11973491&rft_id=info%3Apmid%2F11973491&rft.externalDocID=11973491
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0143-3636&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0143-3636&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0143-3636&client=summon